- Home
- VINP vs NVCT Comparison
VINP vs NVCT Comparison
Compare VINP & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VINP | NVCT |
|---|---|---|
| Founded | 2009 | 2020 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 638.8M | 617.7M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VINP | NVCT |
|---|---|---|
| Price | $9.68 | $24.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $14.00 | $10.00 |
| AVG Volume (30 Days) | 40.2K | ★ 176.1K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.72% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.07 | N/A |
| Revenue Next Year | $12.74 | N/A |
| P/E Ratio | $24.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.19 | $5.55 |
| 52 Week High | $13.61 | $29.28 |
Technical Indicators
Market Signals| Indicator | VINP | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 54.38 | 60.20 |
| Support Level | $9.76 | $17.98 |
| Resistance Level | $10.26 | $25.94 |
| Average True Range (ATR) | 0.27 | 1.60 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 77.16 | 74.83 |
Price Performance
Historical ComparisonAbout VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.